ARWR - Chief Executive Officer at Arrowhead Pharma Acquires Company Stock Options Worth 57555 Shares | Benzinga
Christopher Anzalone, Chief Executive Officer at Arrowhead Pharma (NASDAQ:ARWR), reported a large acquisition of company stock options on September 20, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Anzalone, Chief Executive Officer at Arrowhead Pharma, a company in the Health Care sector, was just awarded stock options worth 57,555 shares of ARWR. The options give Anzalone the right to buy the company's stock at $4.75 per share.
Arrowhead Pharma shares are trading down 0.81% at $26.79 at the time of this writing on Thursday morning. Since the current price is $26.79, this makes Anzalone's 57,555 ...